İkBal Turker

İkBal Turker

Auto-generated profile, based on publicly available information

İkBal Turker

Division of Pediatric Critical Care, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Journal of Emergency Medicine Case Reports
Verified
Journal Article
Closed access
EÇEzgi Çay
Ezgi Çay
ITİkBal Türker
İkBal Türker
FEFaruk Eki̇nci̇
Faruk Eki̇nci̇
SBSevcan Bi̇len
Sevcan Bi̇len
OHOzden Ozgur Horoz
Ozden Ozgur Horoz
DYDinçer Yıldızdaş
Dinçer Yıldızdaş
Pregabalin is a drug used to treat neuropathic pain, epilepsy, and fibromyalgia. However, the number of reported cases of pregabalin abuse is steadily growing. This case showed dystonia, an effect not previously documented as a consequence of pregabalin administration. A 16-year-old male patient with no known pre-existing medical conditions was admitted to the pediatric emergency department for the first time, complaining of drowsiness caused by pregabalin abuse. During the patient's follow-up, dystonia was observed, and biperiden was administered at a repeating dose. Subsequently, he was moved to the pediatric intensive care unit (PICU) for further tests and treatment. After three days of follow-up, the patient was discharged due to the absence of complaints. This case report presents dystonia resulting from pregabalin abuse, a condition that has not previously been documented in the literature.

29 December 2025 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
HTHasan Ali Telefon
Hasan Ali Telefon
ITİkBal Turker
İkBal Turker
FEFaruk Ekinci
Faruk Ekinci
OHOzden Ozgur Horoz
Ozden Ozgur Horoz
DYDincer Yildizdas
Dincer Yildizdas

30 September 2023 in Cukurova Medical Journal
Verified
Journal Article
Open access
PDF file
NSNursel Sürmelioğlu
Nursel Sürmelioğlu
HSHatice Yağmur SOYSAL
Hatice Yağmur SOYSAL
ITİkBal Türker
İkBal Türker
FEFaruk Eki̇nCi̇
Faruk Eki̇nCi̇
OHOzden Ozgur Horoz
Ozden Ozgur Horoz
DYDinçer Yildizdaş
Dinçer Yildizdaş
Purpose: The aim of this study was to determine the drug-drug interactions that are frequently encountered in critically ill patients and the factors that predict these interactions. Materials and Methods: All patients who were admitted to the pediatric intensive care unit (13 bed) of a university hospital and used more than one drug in their treatment were included in this prospective and cross-sectional study. Patients' demographics, laboratory findings, and medications included in their treatment were evaluated daily by a clinical pharmacist. The UpToDate® database was used to detect potential drug interactions. Results: During the study, 797 potential drug-drug interactions were detected in 55 (83.33%) of 66 patients followed. All these interactions were evaluated by the clinical pharmacist and 114 recommendations were made to the physicians following the treatment regarding these potential interactions. Eighty-five (74.56%) of these recommendations were accepted by physicians. Within the scope of the study, each patient was followed up for a median of 9 (2-63) days, and the median value of potential drug interactions detected during this period was calculated as 7 (1-89). Conclusion: The existence of pDDIs was significantly associated with the number of prescribed medications. Exposure to pDDIs is frequent in critically ill pediatric patients and related to the number of medications. Daily and close cooperation between clinicians and clinical pharmacists is recommended to prevent harmful outcomes of DDIs. In order to minimize this risk, it is recommended to avoid polypharmacy as much as possible and to offer alternatives to inducer and inhibitor drugs in treatment.

16 June 2026 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
FEFaruk Eki̇nCi̇
Faruk Eki̇nCi̇
DYDi̇nÇer Yildizdaş
Di̇nÇer Yildizdaş
OHOzden Ozgur Horoz
Ozden Ozgur Horoz
HYHayri̇ Levent Yilmaz
Hayri̇ Levent Yilmaz
SBSevcan Bi̇lEn
Sevcan Bi̇lEn
ZÖZeynelabi̇dİn Öztürk
Zeynelabi̇dİn Öztürk
Background/aim: Colchicine poisoning has been associated with systemic toxicity, multiple organ dysfunction syndrome (MODS), and mortality. In the present study, the demographic, clinical, and laboratory characteristics of pediatric colchicine poisoning cases and the incidence of organ failure are investigated to identify potential risk factors associated with MODS. Materials and methods: Included in this retrospective multicenter cohort study were pediatric patients admitted to 28 tertiary-care pediatric intensive care units with a diagnosis of colchicine poisoning. Demographic data, clinical and laboratory findings, and clinical outcomes were extracted from medical records. MODS was defined as dysfunction involving at least two organ systems. Multivariable logistic regression analysis was performed to identify the variables independently associated with MODS. Results: Of the 150 patients included in the study, 40% were younger than 5 years and 52% were older than 13 years. Gastrointestinal symptoms were most prominent, with nausea and vomiting observed in 64.7%, abdominal pain in 36.7%, and diarrhea in 24%. Overall, 66% developed no organ failure, while single-organ failure occurred in 7.3% and 26.7% developed MODS. The coagulation system was most frequently affected (26%), followed by the hematological (19.3%) and immunological (18%) systems. Multivariable logistic regression analysis identified the baseline PRISM III score, ingested colchicine dose per kilogram of body weight, and initial sodium, creatinine, and aspartate aminotransferase (AST) levels as independent predictors of MODS. Conclusion: MODS can develop at ingestion doses lower than 0.5 mg/kg, which have historically been considered safe. Higher ingested doses and elevated PRISM III scores were associated with MODS, although these findings are derived from retrospective observational data and should not be interpreted as causal or as direct clinical recommendations. Further prospective studies are needed to clarify relevant doses, interventions, and prognostic factors in pediatric colchicine poisoning associated with MODS.